A Novel Virus-Based Expression System

The present invention is related to a recombinant viral vector for vaccines.

Currently available poxvirus vectors for humans and other animals exhibit suboptimal expression of recombinant gene(s) and high expression of vector proteins which causes weak immunogenicity and high anti-vector immune response.

The present novel virus-based expression vectors are non-replicating in human and animals, have high expression of exogenous genes to achieve strong immunogenicity, demonstrate low expression of vector proteins to minimize anti-vector immune responses and minimize competition with expression of recombinant proteins and are capable of stable propagation in a continuous cell line. The present virus based expression vectors may be suitable for manufacturing vaccines for inducing an immune response in vaccinated individuals.

Potential Commercial Applications:		Competitive Advantages:
Vaccine Tool for studying immune responses		Non-replicating in human and animals Achieve high expression of recombinant genes Low expression of vector genes Stable propagation in a continuous cell line

Development Stage:

• Early-stage
• In vitro data available
• Prototype

Related Invention(s):
E-402-1986-1
E-552-1982-2


Inventors:

Bernard Moss (NIAID)  ➽ more inventions...

Linda Wyatt (NIAID)  ➽ more inventions...


Intellectual Property:
PCT Application No. PCT/US2015/052295
US Application No. 62/055,989
US Application No. 15/514,119

Collaboration Opportunity:
The National Institute of Allergy and Infectious Diseases, Laboratory of Viral Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize A Novel Virus-Based Expression System. For collaboration opportunities, please contact Chris Kornak at chris.kornak@nih.gov.


Licensing Contact:
Benjamin Hurley, Ph.D.
Email: benjamin.hurley@nih.gov
Phone: 240-669-5092

OTT Reference No: E-181-2014-0
Updated: Aug 18, 2015